Barclays
ADMA icon

Barclays’s ADMA Biologics ADMA Stock Holding History

Barclays’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-22,500
Closed -$85K – 6900
2019
Q1 		$85K Buy
+22,500
New +$79.5K ﹤0.01% 5489

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Barclays's ADMA Position: Q2 2026 in Review

Barclays reduced its ADMA Biologics (ADMA) stake by 40% in Q2 2026, selling an estimated $519K and leaving 86,894 shares worth $727K. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

Barclays first reported a position in ADMA in Q1 2018 and has held it in 34 quarters since. The position peaked at $14.5M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Barclays held 86,894 shares of ADMA Biologics worth $727K as of Q2 2026.
  • Barclays sold 56,968 ADMA Biologics shares in Q2 2026, an estimated $519K.
  • ADMA Biologics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2979 holding.
  • Barclays first reported a position in ADMA Biologics in Q1 2018 and has held it in 34 quarters since.
  • Barclays's ADMA Biologics position peaked at $14.5M in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.